This study uses the CCR model and BCC model of the Data Envelopment Analysis (DEA) to evaluate and analyze the performance efficiency of the listed, OTC and emerging biotechnology and medicine companies in Taiwan, in terms of overall technical efficiency, pure technical efficiency and scale efficiency. The findings can provide the operators with relative inefficiency with learning examples and references for improvements. In addition, this study combines the DEA and Technique for Order Preference by Similarity to Ideal Solution (TOPSIS) into the DEA/TOPSIS approach. The biotechnology and medicine firms whose efficiency value in the CCR model is equal to 1 were selected to build the performance evaluation model for the operators. The findings can provide the operators and investors with the references for choosing and investing in the biotechnology and medicine firms in the future. The results of this study show that the company enjoying the best performance is ScinoPharm Taiwan Ltd. in the pharmaceutical industry, Jinghua in the medical devices industry, and Grape King Bio Ltd. in the applied biotechnology industry. They can serve as the learning examples for other companies with poor efficiency and references for the investors when choosing and investing in the biotechnology and medicine firms in the future.
